top of page

New Hope Against Pancreatic Cancer: The Latest in Treatment and Technology

Nov 1
4 min read

November is Pancreatic Cancer Awareness Month, and this year there's more reason for hope than ever before.

Pancreatic cancer has long been one of the hardest cancers to treat. Each year in the U.S., about 60,000 people are diagnosed and about 50,000 die from the disease, and the five-year survival rate is 13%. For decades, progress came slowly.

But 2026 has brought real breakthroughs: a first-of-its-kind targeted drug, encouraging long-term results from a personalized cancer vaccine, and new technology that may catch the disease years earlier. Here's a look at what's changing, and why it matters.

Why pancreatic cancer is so hard to treat

  1. It's found late. The pancreas sits deep in the abdomen, and there's no routine screening test for people without symptoms. About 80% of patients are diagnosed after the disease has advanced, when surgery is usually no longer possible.

  2. Symptoms are vague. Early signs, if any, are easy to mistake for other problems.

  3. It resists standard treatment. Pancreatic tumors build a protective environment that shields them from chemotherapy and the immune system.

  4. One mutation drives most cases. The vast majority of pancreatic cancers are fueled by changes in a gene called KRAS, part of the RAS family. For decades, RAS was considered "undruggable." That's what makes this year's news so significant.

A breakthrough drug: daraxonrasib (Rasonque)

The biggest pancreatic cancer news of 2026 is a once-daily pill called daraxonrasib, sold as Rasonque and developed by Revolution Medicines.

What it does: Rather than targeting just one specific mutation, daraxonrasib is designed to block active RAS signaling across several common mutation types, shutting down a key signal that tells cancer cells to keep growing.

What the research showed: In the phase 3 RASolute 302 trial of about 500 people whose metastatic pancreatic cancer had progressed after chemotherapy, daraxonrasib cut the risk of death by 60% compared with standard chemotherapy. Median survival was 13.2 months versus 6.7 months, nearly double. Patients also had fewer serious side effects than with chemo and kept a better quality of life for longer. When the results were presented at the American Society of Clinical Oncology meeting in May, doctors gave a standing ovation.

Where it stands: On August 26, 2026, the FDA approved daraxonrasib as the first RAS inhibitor for pancreatic cancer, for adults with metastatic disease who have already had treatment or can't tolerate multi-drug chemotherapy. More trials are now testing it earlier in treatment.

It isn't a cure, and cancer can eventually become resistant. But for people facing advanced pancreatic cancer, extra months with better quality of life are a meaningful step forward, and proof that RAS, once called "undruggable," can be targeted.

A personalized vaccine that teaches the immune system

Pancreatic cancer has historically been one of the cancers least responsive to immunotherapy. A new approach may change that.

What it is: Autogene cevumeran, developed by BioNTech and Genentech, is a personalized mRNA vaccine. After a patient's tumor is surgically removed, researchers read its unique genetic changes and build a custom vaccine that trains the immune system to recognize and attack any remaining cancer cells. It's a treatment vaccine, meant to keep cancer from coming back, not to prevent it in healthy people.

What the research showed: In an early trial led by Dr. Vinod Balachandran at Memorial Sloan Kettering, 8 of 16 patients had a strong immune response to the vaccine. At six years of follow-up, presented in April 2026, nearly all of those responders were still alive, a remarkable result for this disease.

Where it stands: The study was small, so larger trials are needed. A randomized phase 2 trial is now underway at dozens of sites worldwide, comparing the vaccine plus immunotherapy and chemotherapy with chemotherapy alone in people whose tumors have been removed.

New technology for catching it earlier

Because pancreatic cancer is so often found late, earlier detection may be the most powerful tool of all. Two advances stand out this year.

AI that reads CT scans. Mayo Clinic researchers developed an artificial intelligence model called REDMOD that looks for subtle changes on routine abdominal CT scans, changes too small for the human eye to notice. In a study published in Gut in June 2026, the model reviewed nearly 2,000 scans that had originally been read as normal. It spotted 73% of the cancers that were later diagnosed, a median of about 16 months early, nearly twice the rate of specialists reviewing the same scans. It's now being tested in a clinical trial for people at higher risk.

A blood test for early-stage disease. Researchers at City of Hope developed PANXEON, a blood test that combines three cancer markers with AI analysis. In results published in Nature Medicine in September 2026, it correctly identified stage 1 and 2 pancreatic cancer in 87% of cases. Experts caution that any screening test must avoid false alarms before it's ready for routine use, so more research is underway.

Neither is available as a routine screening test yet, but both could one day help find pancreatic cancer while it's still treatable with surgery.

Know the signs

Until routine screening exists, knowing the warning signs matters. Talk with your doctor if you notice:

  1. Yellowing of the skin or eyes (jaundice)

  2. Pain in the upper abdomen that may spread to the back

  3. Unexplained weight loss or loss of appetite

  4. New-onset diabetes, especially after age 50

  5. Dark urine, pale or greasy stools, or itchy skin

These symptoms often have other causes, but they're worth checking. People with a family history of pancreatic cancer, certain inherited gene changes, chronic pancreatitis or long-standing diabetes may also want to ask their doctor about extra monitoring.

How you can help

  1. Wear purple this November to raise awareness.

  2. Share what you've learned with friends and family.

  3. Support research through organizations like the Pancreatic Cancer Action Network (pancan.org).

  4. Take care of yourself. Not smoking, staying active and maintaining a healthy weight can lower your risk.

Hope for the future

For years, pancreatic cancer meant few options and little progress. This year, that began to change. A targeted pill that nearly doubles survival, a vaccine with lasting results and tools that may find the disease years earlier are giving patients, families and doctors something they haven't had in a long time: real hope.

This month, we're thinking of everyone touched by pancreatic cancer in our community. 💜

This article is for general information and isn't medical advice. If you have symptoms or questions about your risk, please talk with your doctor.

 
 
 

Comments


bottom of page